S-trans,trans-Farnesylthiosalicylic acid (FTS) is a novel farnesylated rigid carboxylic acid derivative. In cell-free systems, it acts as a potent competitive inhibitor (K = 2.6 µM) of the enzyme prenylated protein methyltransferase (PPMTase), which methylates the carboxyl-terminal S-prenylcysteine in a large number of prenylated proteins including Ras. In such systems, FTS inhibits Ras methylation but not Ras farnesylation. Inhibition of the PPMTase by FTS in homogenates or membranes of a variety of tissues and cell lines is inferred from a block in the methylation of exogenously added substrates such as N-acetyl-S-trans,trans-farnesyl-L-cysteine and of endogenous substrates including small GTP-binding proteins. FTS can also inhibit methylation of these proteins in intact cells (e.g. in Rat-1 fibroblasts, Ras-transformed Rat-1, and B16 melanoma cells). Unlike in cell-free systems, however, relatively high concentrations of FTS (50-100 µM) are required for partial blocking (10-40%) of protein methylation in the intact cells. Thus, FTS is a weak inhibitor of methylation in intact cells. Because methylation is the last step in the processing of Ras and related proteins, FTS is not likely to affect steps that precede it, e.g. protein prenylation. This may explain why the growth and gross morphology of a variety of cultured cell types (including Chinese hamster ovary, NIH3T3, Rat1, B16 melanoma, and PC12) is not affected by up to 25 µM FTS and is consistent with the observed lack of FTS-induced cytotoxicity. Nevertheless, FTS reduces the levels of Ras in cell membranes and can inhibit Ras-dependent cell growth in vitro, independently of methylation. It inhibits the growth of human Ha-ras-transformed cells (EJ cells) and reverses their transformed morphology in a dose-dependent manner (0.1-10 µM). The drug does not interfere with the growth of cells transformed by v-Raf or T-antigen but inhibits the growth of ErbB2-transformed cells and blocks the mitogenic effects of epidermal and basic fibroblast growth factors, thus implying its selectivity toward Ras growth signaling, possibly via modulation of Ras-Raf communication. Taken together, the results raise the possibility that FTS may specifically interfere with the interaction of Ras with a farnesylcysteine recognition domain in the cell membrane. This drug, and perhaps other farnesylated rigid carboxylic acid analogs, may be used for in vitro characterization of the PPMTase and for the identification of a putative Ras farnesylcysteine recognition domain in cell membranes.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				M. Maher, H. Ao, T. Banke, N. Nasser, N.-T. Wu, J. G. Breitenbucher, S. R. Chaplan, and A. D. Wickenden Activation of TRPA1 by Farnesyl Thiosalicylic Acid Mol. Pharmacol., April 1, 2008; 73(4): 1225 - 1234. [Abstract] [Full Text] [PDF]

				L. Zhang and R. P. Hill Hypoxia Enhances Metastatic Efficiency in HT1080 Fibrosarcoma Cells by Increasing Cell Survival in Lungs, Not Cell Adhesion and Invasion Cancer Res., August 15, 2007; 67(16): 7789 - 7797. [Abstract] [Full Text] [PDF]

				Z. Ji, F. C. Mei, J. Xie, and X. Cheng Oncogenic KRAS Activates Hedgehog Signaling Pathway in Pancreatic Cancer Cells J. Biol. Chem., May 11, 2007; 282(19): 14048 - 14055. [Abstract] [Full Text] [PDF]

				M. Chu, J. Guo, and C.-Y. Chen Long-term Exposure to Nicotine, via Ras Pathway, Induces Cyclin D1 to Stimulate G1 Cell Cycle Transition J. Biol. Chem., February 25, 2005; 280(8): 6369 - 6379. [Abstract] [Full Text] [PDF]

				L. P. McMahon, W. Yue, R. J. Santen, and J. C. Lawrence Jr Farnesylthiosalicylic Acid Inhibits Mammalian Target of Rapamycin (mTOR) Activity Both in Cells and in Vitro by Promoting Dissociation of the mTOR-Raptor Complex Mol. Endocrinol., January 1, 2005; 19(1): 175 - 183. [Abstract] [Full Text] [PDF]

				M. R. Philips Methotrexate and Ras Methylation: A New Trick for an Old Drug? Sci. Signal., March 23, 2004; 2004(225): pe13 - pe13. [Abstract] [Full Text] [PDF]

				J. George, J. Sack, I. Barshack, P. Keren, I. Goldberg, R. Haklai, G. Elad-Sfadia, Y. Kloog, and G. Keren Inhibition of Intimal Thickening in the Rat Carotid Artery Injury Model by a Nontoxic Ras Inhibitor Arterioscler. Thromb. Vasc. Biol., February 1, 2004; 24(2): 363 - 368. [Abstract] [Full Text]

				P. H. M. Lommerse, G. A. Blab, L. Cognet, G. S. Harms, B. E. Snaar-Jagalska, H. P. Spaink, and T. Schmidt Single-Molecule Imaging of the H-Ras Membrane-Anchor Reveals Domains in the Cytoplasmic Leaflet of the Cell Membrane Biophys. J., January 1, 2004; 86(1): 609 - 616. [Abstract] [Full Text] [PDF]

				M. Forsberg, P. Druid, L. Zheng, O. Stendahl, and E. Sarndahl Activation of Rac2 and Cdc42 on Fc and complement receptor ligation in human neutrophils J. Leukoc. Biol., October 1, 2003; 74(4): 611 - 619. [Abstract] [Full Text] [PDF]

				H. C. Clarke, H. M. Kocher, A. Khwaja, Y. Kloog, H. T. Cook, and B. M. Hendry Ras Antagonist Farnesylthiosalicylic Acid (FTS) Reduces Glomerular Cellular Proliferation and Macrophage Number in Rat Thy-1 Nephritis J. Am. Soc. Nephrol., April 1, 2003; 14(4): 848 - 854. [Abstract] [Full Text] [PDF]

				K. Kramer, E. O. Harrington, Q. Lu, R. Bellas, J. Newton, K. L. Sheahan, and S. Rounds Isoprenylcysteine Carboxyl Methyltransferase Activity Modulates Endothelial Cell Apoptosis Mol. Biol. Cell, March 1, 2003; 14(3): 848 - 857. [Abstract] [Full Text] [PDF]

				J. George, A. Afek, P. Keren, I. Herz, I. Goldberg, R. Haklai, Y. Kloog, and G. Keren Functional Inhibition of Ras by S-trans,trans-Farnesyl Thiosalicylic Acid Attenuates Atherosclerosis in Apolipoprotein E Knockout Mice Circulation, May 21, 2002; 105(20): 2416 - 2422. [Abstract] [Full Text] [PDF]

				M. Gana-Weisz, J. Halaschek-Wiener, B. Jansen, G. Elad, R. Haklai, and Y. Kloog The Ras Inhibitor S-trans,trans-Farnesylthiosalicylic Acid Chemosensitizes Human Tumor Cells Without Causing Resistance Clin. Cancer Res., February 1, 2002; 8(2): 555 - 565. [Abstract] [Full Text] [PDF]

				J. A. Rosado, I. Rosenzweig, S. Harding, and S. O. Sage Tumor necrosis factor-{alpha} inhibits store-mediated Ca2+ entry in the human hepatocellular carcinoma cell line HepG2 Am J Physiol Cell Physiol, June 1, 2001; 280(6): C1636 - C1644. [Abstract] [Full Text] [PDF]

				C. W. M. Reuter, M. A. Morgan, and L. Bergmann Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood, September 1, 2000; 96(5): 1655 - 1669. [Abstract] [Full Text] [PDF]

				B. Jansen, H. Schlagbauer-Wadl, H. Kahr, E. Heere-Ress, B. X. Mayer, H.-G. Eichler, H. Pehamberger, M. Gana-Weisz, E. Ben-David, Y. Kloog, et al. Novel Ras antagonist blocks human melanoma growth PNAS, November 23, 1999; 96(24): 14019 - 14024. [Abstract] [Full Text] [PDF]

				H. Niv, O. Gutman, Y. I. Henis, and Y. Kloog Membrane Interactions of a Constitutively Active GFP-Ki-Ras 4B and Their Role in Signaling. EVIDENCE FROM LATERAL MOBILITY STUDIES J. Biol. Chem., January 15, 1999; 274(3): 1606 - 1613. [Abstract] [Full Text] [PDF]

				D. N. Crowell, S. E. Sen, and S. K. Randall Prenylcysteine alpha -Carboxyl Methyltransferase in Suspension-Cultured Tobacco Cells Plant Physiology, September 1, 1998; 118(1): 115 - 123. [Abstract] [Full Text]

				J. A. Rosado and S. O. Sage Regulation of Plasma Membrane Ca2+-ATPase by Small GTPases and Phosphoinositides in Human Platelets J. Biol. Chem., June 23, 2000; 275(26): 19529 - 19535. [Abstract] [Full Text] [PDF]

				J. A. Rosado, T. Porras, M. Conde, and S. O. Sage Cyclic Nucleotides Modulate Store-mediated Calcium Entry through the Activation of Protein-tyrosine Phosphatases and Altered Actin Polymerization in Human Platelets J. Biol. Chem., May 4, 2001; 276(19): 15666 - 15675. [Abstract] [Full Text] [PDF]

				J. A. Rosado and S. O. Sage Role of the ERK Pathway in the Activation of Store-mediated Calcium Entry in Human Platelets J. Biol. Chem., May 4, 2001; 276(19): 15659 - 15665. [Abstract] [Full Text] [PDF]